Preliminary development of a live attenuated canine parvovirus vaccine from an isolate of British origin.
Canine parvovirus isolated from a case of haemorrhagic enteritis in a breeding kennel in England was passaged and cloned in cultured feline and canine cells. No significant evidence of pathogenicity was found during six serial passages of the modified virus back through young dogs. The attenuated virus was excreted by inoculated animals and spread rapidly to uninoculated animals held in contact. When high titre attenuated virus was given to the six-week-old offspring of a seropositive dam a prompt seroconversion was observed. When the attenuated virus was used as an experimental vaccine in 108 pups in an infected breeding colony a highly significant improvement was obtained in the accumulated morbidity and mortality compared with a parallel group vaccinated with modified live feline panleucopenia virus.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D002415:Cats; D004283:Dog Diseases / Q000382:microbiology / Q000517:prevention & control*; D004285:Dogs; D010321:Parvoviridae / Q000276:immunology / Q000302:isolation & purification; D010322:Parvoviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D006113:United Kingdom; D014611:Vaccination / Q000662:veterinary; D014613:Vaccines, Attenuated
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated